Health Canada Approves DENOZA, Apotex's Denosumab Biosimilar for Osteoporosis Treatment
核心洞察
Health Canada has approved DENOZA (搜索) (denosumab injection), a biosimilar to Prolia, for treating postmenopausal women and men with osteoporosis (搜索) at high risk for fracture.
The approval by Apotex (搜索) addresses a significant public health need, as osteoporosis (搜索) affects more than 2.3 million Canadians and remains an underdiagnosed condition.
DENOZA (搜索) will be available in prefilled syringe format and aims to improve patient access to osteoporosis (搜索) therapies while contributing to healthcare system sustainability.
Apotex (搜索) Inc., Canada's largest pharmaceutical company, announced that Health Canada has approved DENOZA (搜索) (denosumab injection), a biosimilar to Prolia, for treating osteoporosis (搜索) in high-risk patients. The approval covers treatment of postmenopausal women with osteoporosis at high risk for fracture and osteoporosis in men at high risk for fracture, along with all remaining indications of the reference biologic as outlined in the Product Monograph.
Addressing a Critical Public Health Need
The approval comes at a crucial time for Canadian healthcare, as osteoporosis (搜索) affects more than 2.3 million Canadians. "Osteoporosis is a significant public health issue, affecting more than 2.3 million Canadians," said Martin Arès, President, Apotex (搜索) Canada and Rest of World. "The approval of DENOZA (搜索) reflects our continued commitment to helping improve access to treatment options and contributing to a sustainable healthcare system, while offering healthcare professionals and patients additional choices in care."
DENOZA (搜索) will be available in a prefilled syringe format, providing healthcare professionals and patients with an additional treatment option in the osteoporosis (搜索) care landscape.
Expert Endorsement for Expanded Access
Leading osteoporosis (搜索) specialists have welcomed the approval as a significant step forward in patient care. Dr. Angela M. Cheung, Professor of Medicine, KY and Betty Ho Chair in Integrative Medicine at University of Toronto, Senior Physician Scientist at University Health Network, and Founding Director of the University Health Network Osteoporosis Program, emphasized the clinical importance of the approval.
"Timely access to osteoporosis (搜索) therapies plays an important role in supporting patient care and helping reduce the impact of this underdiagnosed condition," Dr. Cheung stated. "The introduction of additional treatment options, including biosimilars such as DENOZA (搜索), can support healthcare providers and patients by broadening available choices within the current treatment landscape."
Healthcare System Impact
Dr. Famida Jiwa, President and CEO of Osteoporosis Canada (搜索), also endorsed the approval, highlighting its potential impact on the Canadian healthcare system. "Expanding access to therapies is an important step in supporting Canadians living with osteoporosis (搜索)," Dr. Jiwa noted. "The approval of DENOZA (搜索) adds another option to the range of treatments available within the healthcare system."
The biosimilar approval aligns with Apotex (搜索)'s mission as a "Force for Health," focusing on patient access to appropriate treatment options as a core component of their healthcare strategy.
Clinical Considerations
Healthcare professionals are advised to refer to the complete Product Monograph for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements associated with DENOZA (搜索) treatment.
The approval represents Apotex (搜索)'s continued expansion in the biosimilar market, building on their portfolio of generic, biosimilar, and innovative branded pharmaceuticals designed to improve access to affordable medicines for patients worldwide.